- Home
- GLPG vs IVT Comparison
GLPG vs IVT Comparison
Compare GLPG & IVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- IVT
- Stock Information
- Founded
- GLPG 1999
- IVT 2005
- Country
- GLPG Belgium
- IVT United States
- Employees
- GLPG N/A
- IVT N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- IVT Real Estate Investment Trusts
- Sector
- GLPG Health Care
- IVT Real Estate
- Exchange
- GLPG Nasdaq
- IVT Nasdaq
- Market Cap
- GLPG 2.1B
- IVT 2.1B
- IPO Year
- GLPG 2005
- IVT N/A
- Fundamental
- Price
- GLPG $30.42
- IVT $27.67
- Analyst Decision
- GLPG Hold
- IVT Hold
- Analyst Count
- GLPG 4
- IVT 5
- Target Price
- GLPG $31.33
- IVT $32.00
- AVG Volume (30 Days)
- GLPG 169.3K
- IVT 578.9K
- Earning Date
- GLPG 11-05-2025
- IVT 10-28-2025
- Dividend Yield
- GLPG N/A
- IVT 3.44%
- EPS Growth
- GLPG N/A
- IVT 1421.59
- EPS
- GLPG N/A
- IVT 1.51
- Revenue
- GLPG $336,643,201.00
- IVT $293,020,000.00
- Revenue This Year
- GLPG $1.77
- IVT $9.58
- Revenue Next Year
- GLPG $0.44
- IVT $6.83
- P/E Ratio
- GLPG N/A
- IVT $18.28
- Revenue Growth
- GLPG 10.31
- IVT 9.60
- 52 Week Low
- GLPG $22.36
- IVT $25.21
- 52 Week High
- GLPG $37.78
- IVT $31.65
- Technical
- Relative Strength Index (RSI)
- GLPG 41.14
- IVT 44.59
- Support Level
- GLPG $30.17
- IVT $27.72
- Resistance Level
- GLPG $33.12
- IVT $28.34
- Average True Range (ATR)
- GLPG 0.75
- IVT 0.57
- MACD
- GLPG -0.04
- IVT 0.04
- Stochastic Oscillator
- GLPG 22.55
- IVT 53.27
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About IVT InvenTrust Properties Corp.
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.